Filana Therapeutics (FLNA) Total Non-Current Liabilities (2010 - 2026)

Filana Therapeutics has reported Total Non-Current Liabilities for 8 years, with the latest figure at $40.2 million in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 15.16% year-over-year to $40.2 million in Q2 2026; TTM through Jun 2026 was $40.2 million, a 15.16% decrease from a year earlier, with the FY2025 full-year figure at $43.8 million, up 273.06% from the prior year.
• Total Non-Current Liabilities was $40.2 million for Q2 2026 at Filana Therapeutics, roughly flat from $40.1 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $57.0 million in Q3 2024, with the low at $6.9 million in Q1 2022.
• Average Total Non-Current Liabilities over 5 years is $25.2 million, with a median of $14.2 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities sank 43.99% in 2022, then soared 273.06% in 2025.
• Over 5 years, Total Non-Current Liabilities stood at $7.1 million in 2022, then soared by 99.99% to $14.2 million in 2023, then slipped by 17.22% to $11.8 million in 2024, then jumped by 273.06% to $43.8 million in 2025, then dropped by 8.39% to $40.2 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $40.2 million (Q2 2026), $40.1 million (Q1 2026), and $43.8 million (Q4 2025), per Business Quant data.